Evaluation of Treatment with Direct Thrombin Inhibitors in Patients with Heparin‐Induced Thrombocytopenia

Abstract

All three drugs were effective as anticoagulants for patients with HIT or presumed HIT. Based on average use and average wholesale price, bivalirudin cost less per day than the other two agents. Although not yet approved by the United States Food and Drug Administration for management of HIT, bivalirudin appears to be a viable treatment alternative for anticoagulation therapy.